Edition:
United States

Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant


Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Minerva Neurosciences Inc ::Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant (min-202) as adjunctive therapy in patients with major depressive disorder.Minerva Neurosciences Inc - approximately 280 patients are planned to be enrolled at more than 85 clinical sites in U.S., Europe, Russia and Japan.